Access cutting-edge upper tract urothelial cancer treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access upper tract urothelial cancer specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related upper tract urothelial cancer treatment provided free
This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC), preferring to forego standard of care radical nephroureterectomy (RNU) surgery. Currently these patients would not be suitable candidates for neoadjuvant trials, as the patients intention is to forego surgery. The patients are also not candidates for metastatic trials, a
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Check if you qualify for this upper tract urothelial cancer clinical trial in Washington Dc, DC
If you're searching for upper tract urothelial cancer treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced upper tract urothelial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.